Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.54, while Regeneron Pharmaceuticals Inc trades at $796.76 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEI | REGN | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $120.72 | $812.27 |
52-Week Low | $116.16 | $555.51 |
Market Cap | — | $82.06B |
Enterprise Value | — | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.565, up 0.27% today, with technical indicators showing a bearish trend from moving averages and neutral oscillators. Recent news highlights institutional activity, including Bank of America increasing its stake by 39.7% in the latest quarter (Defense World, 2026-08-01). The fund maintains a conservative profile with regular dividend distributions, appealing to income-focused investors amid volatile bond markets.
The outlook for IEI is cautious due to rising Treasury yields and inflation concerns, posing risks from potential Fed rate hikes. However, its government backing and lower volatility offer stability for risk-averse portfolios, with income generation from dividends remaining a key attraction despite macroeconomic headwinds.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
